Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date: December 11, 2023
Context: The filing discloses the presentation of clinical data at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition regarding the Company's lead candidate, DISC-0974, for the treatment of myelofibrosis (MF).
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The filing reports initial data from the ongoing Phase 1b/2 study of DISC-0974 in patients with myelofibrosis (NCT05320198). Data reflects 11 evaluable subjects from the initial three dose levels (14 mg, 28 mg, and 50 mg) as of the October 20, 2023 cutoff.
- Hepcidin and Iron Regulation: Dosing resulted in meaningful, dose-dependent decreases in hepcidin and corresponding increases in serum iron.
- 28 mg Dose Efficacy: Patients dosed with 28 mg experienced a >75% reduction in serum hepcidin and a >75% increase in serum iron.
- Hemoglobin Response: Four of seven (57%) evaluable non-transfusion-dependent (NTD) patients at the 28 mg and 50 mg dose levels achieved a hemoglobin increase of ≥ 1.5 g/dL from baseline.
- Transfusion Independence: One of two transfusion-dependent (TD) patients achieved transfusion independence by the Gale Criteria.
- JAK Inhibitor Concomitance: Hematologic activity was observed regardless of whether patients were receiving concomitant janus kinase (JAK) inhibitor therapy.
- Safety Profile: DISC-0974 was generally well-tolerated. Adverse events (AEs) seen in two or more subjects included fatigue, anemia, diarrhea, and nausea. The majority of AEs were deemed not related to DISC-0974.
Guidance, Outlook, and Risks
Outlook: The Company indicated that dose escalation is ongoing. A conference call was held to review data and operational plans.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Key risks include:
- Clinical trial results may not be predictive of future results or support further development and marketing approval.
- Uncertainties regarding the timing of data release and trial completion.
- General risks associated with the research, development, and commercialization of product candidates.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis of the clinical data.
- Review the archived webcast of the December 11, 2023 conference call for management's specific commentary on the data.
- Monitor subsequent filings for updates on the Phase 1b/2 dose-escalation timeline and patient enrollment numbers.
- Assess the safety profile details in the full clinical study report when available, specifically regarding the frequency and severity of anemia and fatigue.
- Check the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide financial figures.